This is in part due to its high expression on neoplastic plasma cells and late mature B-cells [28], and the prominent role of B-cell activating factor and A proliferation-inducing ligand-mediated activation of BCMA in promoting myeloma cell survival and therefore BCMA-dependence in the TME [29]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.